Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Evommune, Inc.

EVMNNYSEEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 17, 2026Accepted Nov 17, 2026, 4:41 PM ESTFiling CIK 2044725Accession 0001290976-26-000006
Share

Structured filing — 4

primarydocument.xml

Open full document ↗

Filing details

Report period
2026-11-13
Issuer
Evommune, Inc.
Issuer CIK
0002044725
Trading symbol
EVMN

Reporting owner 1

Name
KIRSCH ARTHUR S
Reporting owner CIK
0001290976
Relationship
Director
Address
C/O EVOMMUNE, INC., 1891 PAGE MILL ROAD, PALO ALTO, CA, 94304

Derivative transactions

Derivative transactions · 4 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (Right to buy)16.002026-11-13D · Form 4[F1]37,960.00D[F2][F3]2035-11-04Common Stock37,960.000.00D
Stock Option (Right to buy)7.632026-11-13A · Form 4[F1]37,960.00A[F2][F3]2035-11-04Common Stock37,960.0037,960.00D
Stock Option (Right to buy)19.822026-11-13D · Form 4[F4]15,673.00D[F2][F5]2036-06-01Common Stock15,673.000.00D
Stock Option (Right to buy)7.632026-11-13A · Form 4[F4]15,673.00A[F2][F5]2036-06-01Common Stock15,673.0015,673.00D
Table key
D · Form 4
Disposition to the issuer under Rule 16b-3(e)
D
Direct
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired

Footnotes

F1
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.↩ 1↩ 2
F2
The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; and (ii) a Change in Control during the Reporting Person's Continuous Service, each as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.↩ 1↩ 2↩ 3↩ 4
F3
One third (1/3) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.↩ 1↩ 2
F4
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 2, 2026.↩ 1↩ 2
F5
The shares subject to the option award shall vest at the earlier of (i) June 2, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.↩ 1↩ 2

Signature 1

Signed
/s/ Gregory S. Moss, Attorney-in-Fact
Date
2026-11-17

Company context

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.

Current securities

Recent company filings

  1. 4 filingNov 17, 2026
  2. 4 filingNov 17, 2026
  3. 4 filingNov 17, 2026
  4. 4 filingNov 17, 2026
  5. 424B3 filingNov 17, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.